ADC Pharmacokinetics and Clinical Pharmacology Summit

Antibody-drug conjugates (ADCs) have emerged as a rapidly evolving, highly promising class of oncology drugs, with 12 approvals and many more in development. Despite their success, the therapeutic window remains relatively narrow, posing challenges for finding an optimal dose.

In the face of evolving regulatory guidance and more complex ADCs entering development, the inaugural ADC Pharmacokinetics and Clinical Pharmacology Summit comes to life this October to provide in-depth pharmacokinetic and clinical pharmacology insights to help ADC developers select a clinical dose that maximizes efficacy whilst limiting toxicities and drive more ADCs to BLA approval quicker.

As the next generation of ADCs becomes even more complex, this further emphasizes the need for a clear strategy for those working within PK/PD, bioanalysis, pharmacometrics and clinical pharmacology to support the tricky translation from non-clinical studies into clinical trials.

See how others are approaching the early establishment of a clear mechanistic link between ADC design and PK profile, utilizing pharmacometrics and PK/PD data to inform dose optimization for FIH, later phase dosage and ADC combination therapies.

URLs:
Website: https://go.evvnt.com/2465910-0?pid=10018
Tickets: https://go.evvnt.com/2465910-1?pid=10018
Brochure: https://go.evvnt.com/2465910-3?pid=10018

Prices:
Drug Developer Pricing - Conference + Workshop Day: USD 4197.00,
Drug Developer - Conference Only: USD 2999.00,
Academic - Conference + Workshops Day: USD 3597.00,
Academic - Conference Only: USD 2599.00,
Solution Provider - Conference + Workshop Day: USD 5097.00,
Solution Provider - Conference Only: USD 3699.00

Speakers: Alison Betts, Global Head of DMPK and Modeling, Takeda, Andras Strassz, Chief Medical Officer, Heidelberg Pharma Research GmbH, Douglas Leipold, Director - Distinguished Scientific Researcher, Genentech, Earl Albone, Executive Director, Eisai, Hsuan Chang, Senior Scientist, AstraZeneca, Ilse MariaLuce De Salve, Principal Scientist, Merck KGaA, Jeff Kearns, Translational Modeling and Simulation Lead, Novartis AG, Jianzhong Wen, Principal Scientist, Merck and Co, Mike Liao, Pharmacology Team Lead, Global Clinical Pharmacology Lead and BD Diligence Evaluator, Genentech, Niyanta Kumar, Associate Director, Mersana Therapeutics, Rajeev Menon, Executive Director - Scientific and Senior Research Fellow, Abbvie, Sandhya Girish, Vice President, Clinical Pharmacology Sciences, Gilead Sciences, Seema Kumar, Senior Director, Flagship Pioneering, Tushar Garimella, Executive Director, Daiichi Sankyo, Venkatesh Pilla Reddy, Senior Director - Global Pharmacokinetic, Pharmacodynamic and Pharmacometrics, Eli Lilly and Co., Xiaogang Han, Director - Scientific, Drug Metabolism and Pharmacokinetics, Bristol Myers Squibb, Yuting Wang, Senior Scientist, Abbvie, Zuzana Antosova, Director Bioanalysis and Pharmacokinetics, SOTIO Biotech